Pharmacokinetic Parameter | Unita | Total 14C Radioactivity in Plasma after Single Dose | Vatalanib in Plasma at Steady State |
---|---|---|---|
t max | h | 3.5 ± 2.7 | 1.8 ± 1.1 |
2 (median) | 1.5 (median) | ||
C max | μmol/l | 38.3 ± 26.0 | 15.8 ± 9.5 |
μg/mlb | 13.3 ± 9.0 | 5.47 ± 3.29 | |
C min | μmol/l | 1.08 ± 1.49 | |
μg/mlb | 0.375 ± 0.517 | ||
AUC0-24h | μmol · h/l | 487 ± 382 | |
μg · h/mlb | 169 ± 133 | ||
AUC0-∞ or AUCssτ | μmol · h/l | 907 ± 792 | 73.7 ± 59.0 |
μg · h/mlb | 314 ± 275 | 25.6 ± 20.5 | |
Vatalanib AUCssτ/14C AUC ratio | % | 9.0 ± 4.3 | |
Vz/f | liters | 337 ± 234 | |
CLss/f | l/h | 56.1 ± 47.3 | |
Estimated oral absorption | % of dose | 35 (range, 18-57) | |
Blood/plasma 14C radioactivity concentration ratioc | 0.70 ± 0.04 | ||
14C radioactivity confined to red blood cellsc | % | 22 ± 7 | |
Apparent terminal elimination half-life (t1/2λz) | h | 23.4 ± 5.5 | 4.6 ± 1.1 |
Time interval for t1/2λz calculation | h | 12-72 h | 6 or 8 to 24 h |